Feedback (GB:FDBK) has released an update.
Feedback PLC reports a 15% revenue growth for FY2024, reaching £1.2m, with an EBITDA loss improvement exceeding market expectations, despite NHS procurement delays for its novel technology, Bleepa. The company’s cash balance stands strong at £4.3m, and CEO Dr. Tom Oakley expresses optimism for future NHS contracts and international expansion, particularly in India with Bleepa’s medical device classification.
For further insights into GB:FDBK stock, check out TipRanks’ Stock Analysis page.
